Compounded GLP-1 in South Africa: what is legal and what is risky

What is a compounded GLP-1 medicine?

A compounded GLP-1 medicine is a copy of semaglutide or tirzepatide mixed by a pharmacy rather than made by the registered manufacturer. It is not evaluated by SAHPRA, so no regulator has checked what it contains, how sterile it is, or whether the dose in the vial matches the label.

Compounding itself is an ordinary part of pharmacy practice. A pharmacist might prepare a liquid version of a tablet for a child who cannot swallow, or mix a cream in a strength no manufacturer sells. Done for one named patient, on a doctor's authorisation, that is lawful and useful work.

The GLP-1 version is different in kind. Sellers borrowed the word compounding to make factory-style production of unregistered semaglutide and tirzepatide injections sound routine. South African regulators have spent three years saying, in increasingly practical ways, that it is not.

Is compounded GLP-1 legal in South Africa?

Only within limits that the mass-market products do not meet. Section 14(4) of the Medicines Act allows a pharmacist to compound a medicine for a specific patient, on a doctor's authorisation, when the active ingredient already appears in a registered medicine. It does not allow manufacturing at commercial scale for general sale.

The Pretoria High Court tested that boundary in June 2026, in a case Novo Nordisk brought against iDexis, the company trading as Sentra Pharmacy. The court found the pharmacy's compounded semaglutide unlawful: it was made with a synthetic peptide similar, but not identical, to the yeast-derived semaglutide in the registered products, so its active ingredient did not appear in any registered medicine.

SAHPRA has made the same point about salt forms. Products compounded from semaglutide sodium or semaglutide acetate use an ingredient found in no registered medicine, which makes compounding with them illegal. The pattern is consistent: if the exact active ingredient has never passed SAHPRA's scrutiny, preparing it falls outside what compounding may lawfully do.

How does a compounded copy differ from a registered medicine?

The two products may name the same molecule, but everything around the molecule differs. A registered medicine reaches the pharmacy through an approved, audited chain. A compounded copy's chain is whatever the compounder chose, and no outside party has inspected it. The table shows where the gaps sit.

The ingredient row deserves emphasis. When regulators seized the Pretoria facility's stock in May 2026, their findings included illegally imported active ingredients and no analytical testing to confirm identity, potency or purity. Whatever a compounded pen contains, its starting material entered the country outside any approved route.

What has SAHPRA done about compounded GLP-1 products?

SAHPRA has moved in steps: public warnings from December 2023, formal position statements, a social media warning in late 2025, then physical enforcement in 2026 with a joint inspection, a seizure and a Class I recall. Each step narrowed the room in which compounded GLP-1 products could claim legitimacy.

Three years of statements, one court ruling and a seizure point the same way. Any seller still offering compounded GLP-1 products today is trading against explicit, repeated regulatory instruction.

What happened in the 2026 seizure and recall?

On 11 May 2026, inspectors from SAHPRA and the South African Pharmacy Council arrived at iDexis, trading as Sentra Pharmacy in Silverton, Pretoria, and found semaglutide, tirzepatide and combination GLP-1 and GIP injectables being produced and supplied at scale under the banner of compounding. Every GLP-1 and GIP injectable on site was seized.

The regulators' statement was direct: compounding must stay within the legal parameters of the Medicines Act and cannot become a mechanism for large-scale manufacture. The company was instructed to recall affected products from the healthcare providers, pharmacies and other channels it had supplied.

In July 2026 SAHPRA formalised this as a Class I recall, its most serious category, covering compounded semaglutide pens in 0.5 mg, 1 mg and 2 mg strengths, tirzepatide pens in 5 mg, 10 mg and 15 mg strengths, and combination products. Its advice to anyone holding them: stop using or dispensing them immediately and return them to whoever supplied them.

One detail in the recall notice matters for patients. SAHPRA warned that batches distributed before the inspection may be affected beyond those listed, so the safe assumption covers any product from the facility, not only the listed batch numbers.

Do GLP-1 drops or tablets sold on social media work?

No. No oral GLP-1 product of any kind, drops, tablets or capsules, is registered in South Africa, and SAHPRA confirmed in a November 2025 warning that it has not approved any oral GLP-1 solution. Whatever a social media advert claims, a bottle of GLP-1 drops is not a medicine any regulator has assessed.

The chemistry rules drops out on its own. Semaglutide is a peptide that stomach acid breaks down, and it cannot be absorbed from drops held under the tongue. The only oral semaglutide products anywhere are specific tablet formulations built around an absorption enhancer, and none is registered here, as our guide to the Wegovy pill and oral semaglutide explains.

SAHPRA's warning also described how these products are sold: influencer posts and pop-up ads, sellers falsely claiming links to major retail pharmacies, some displaying SAHPRA's own logo, and parcels advertised as shipping from Johannesburg or Cape Town that are actually posted from China. Items that arrive often differ from what was advertised.

What are the risks of using a compounded GLP-1?

The core risk is that nobody has verified what is in the product. SAHPRA's warnings list the possibilities plainly: the wrong amount of active ingredient, harmful substances, no active ingredient at all, or non-sterile material unsuitable for injection. None of these is detectable by looking at a vial or pen.

The United States has the data on what goes wrong. By May 2026 the US FDA had logged more than 900 adverse event reports tied to compounded semaglutide, including dosing errors in which people drew five to twenty times the intended dose from vials that lack the dose counter of a registered pen.

The missing doctor is the other half of the risk. GLP-1 medicines should not be used in pregnancy or while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome, and a history of pancreatitis needs a doctor's judgement first. Nobody screens for any of this at an online checkout.

Even registered products commonly cause nausea, vomiting, diarrhoea and constipation, which is why treatment runs under supervision with follow-up reviews; our guide to managing GLP-1 side effects covers what is normal and what is not. Severe, persistent stomach pain on any GLP-1 product can signal pancreatitis: seek medical care immediately.

Is compounded semaglutide still allowed in the United States?

No, not routinely. US law allowed compounded copies temporarily while the original medicines sat on the official drug shortage list. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for compounding pharmacies ended by May 2025.

That history matters here because local sellers borrowed the American story as legitimacy: if US pharmacies could compound it, the argument ran, a South African one could too. South African law never had a shortage exception of that kind, and the American door has in any case closed.

What remains lawful in the US are narrow, patient-specific exceptions, much like the narrow space South African law allows. Mass-produced copies for general sale fall outside the rules in both countries.

Why is compounded GLP-1 so much cheaper?

The discount is the cost of everything skipped. A registered medicine's price pays for approved ingredient sources, sterile manufacturing, quality testing on every batch, cold-chain distribution and a recall system that can trace a problem to a specific box. A compounded copy skips those layers, and its price advantage measures exactly what was left out.

Registered medicine prices in South Africa are regulated through the Single Exit Price system, which sets one national price per product, so lawful prices sit in a narrow band. An offer far below that band marks a product that got cheap by leaving the regulated system. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

Competition inside the regulated system is what brings lawful costs down. SAHPRA approved a first generic semaglutide in July 2026, registered for type 2 diabetes, and is reviewing a queue of further applications; our guide to generic semaglutide in South Africa covers what that changes. Falling published prices for registered medicine remove the main argument compounded sellers trade on.

How do you check a pharmacy, a seller and a product?

Every link in the legal chain is publicly verifiable. Doctors appear on the HPCSA register, pharmacies and pharmacists on the South African Pharmacy Council register, and registered medicines carry a SAHPRA registration number on the pack. A seller that cannot pass all three checks is not part of the regulated system.

1. Check the pharmacy on the South African Pharmacy Council register. A genuine pharmacy's name and details match the register exactly; a fake's never quite do.
2. Check the doctor behind any assessment on the HPCSA register. A legitimate service will point you to both registers without being asked twice.
3. Check the product. A registered medicine's packaging carries a registration number, and your pharmacist can confirm it against SAHPRA's registered products list.
4. Check the route. Schedule 4 medicines cannot lawfully be sold from a website checkout, a WhatsApp chat or an Instagram page with no doctor involved, whoever the seller claims to be.
5. Report what fails these checks to SAHPRA's 24-hour hotline on 0800 204 307.

The seller-side warning signs, from EFT-only payment to borrowed logos and stolen product photos, are covered in more detail in our guide to what is legal and safe when buying Ozempic online.

What should you do if you have used a compounded GLP-1?

Stop using the product, keep it with its packaging, and speak to a doctor about a safe way forward. SAHPRA's recall advice for the compounded pens is to return them to the pharmacy or provider that supplied them. If you have symptoms that worry you, see a doctor promptly rather than waiting for them to pass.

Tell the doctor exactly what you used, for how long and at what dose, as far as the labelling lets you know it. That history changes real decisions: whether blood tests are worth running, how to time any move to a registered medicine, and what to watch while the last doses clear your system.

Reporting helps the next person. The seller's details, the packaging and screenshots of the advert are all useful to SAHPRA's inspectors, and the hotline takes reports around the clock.

What are the registered GLP-1 options in South Africa?

South Africa has registered GLP-1 medicines for weight management: Wegovy, which is semaglutide and launched here in August 2025; Mounjaro, which is tirzepatide and is registered for both diabetes and weight management; and Saxenda, which is liraglutide. Ozempic is registered for type 2 diabetes, not for weight loss.

All of them are Schedule 4 medicines: a doctor assesses you, confirms a treatment plan where appropriate, and a licensed pharmacy dispenses the medicine. They carry real side effects and exclusions, treatment runs with follow-up reviews, and individual results vary. Which option fits your health picture, if any does, is decided by a doctor on assessment.

The full picture of what is registered and how doctor-led treatment works is in our guide to GLP-1 in South Africa, and how our process works describes what a telehealth assessment involves in practice.

Frequently asked questions